BofA lowered the firm’s price target on Accendra Health (ACH) to $2.50 from $4.70 and keeps an Underperform rating on the shares. Heading into 2026, the firm maintains its positive view on the drug distributor group and updates its price targets to reflect peer group multiple changes.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential